Mounjaro (Tirzepatide) Injection

Mounjaro is a groundbreaking injectable medication containing tirzepatide, a once-weekly treatment developed for managing type 2 diabetes and increasingly used off-label for medical weight loss. It is the first medication to target both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, resulting in enhanced appetite regulation, improved insulin sensitivity, and significant fat reduction.

KEY BENEFITS OF TIRZEPATIDE INJECTIONS

Weight Loss & Appetite Control
Clinical studies show that Tirzepatide can help patients achieve an average weight loss of 15–20% of body weight over several months. It works by reducing appetite, curbing cravings, and helping control portion sizes, making it easier to stick to a balanced diet and sustainable lifestyle.

Metabolic & Cardiovascular Benefits
Beyond weight loss, Tirzepatide improves blood sugar control by lowering HbA1c and fasting glucose levels in patients with type 2 diabetes. It also supports cardiometabolic health by reducing visceral fat and improving cholesterol and blood pressure levels.

You will experience

FAQ's

How does Tirzepatide work?

Tirzepatide mimics two gut hormones—GLP-1 and GIP—that regulate appetite and metabolism. GLP-1 slows digestion, increases satiety, and stimulates insulin release, while GIP enhances GLP-1’s effects, improves insulin sensitivity, and reduces food intake. Together, they signal the brain to reduce hunger, increase fullness, and improve how the body processes sugar and fat.

What is the dosage and administration protocol?

Tirzepatide is given as a subcutaneous injection, either self-administered or at the clinic. It is taken once weekly, on the same day each week. Treatment typically begins at 2.5 mg and is gradually increased to minimize side effects, with maintenance doses up to 15 mg weekly depending on tolerance and response.

Who is an ideal candidate for Tirzepatide?

It is FDA-approved for adults with type 2 diabetes to improve glycemic control and is also prescribed off-label for adults with obesity (BMI ≥30) or overweight (BMI ≥27 with comorbidities) seeking medical weight loss. It is not suitable for patients with type 1 diabetes, a history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2.

What results can I expect?

Patients typically see improved blood sugar control within weeks and steady, progressive weight loss over 8–12 weeks. Maximum results are often achieved at 6–12 months, especially when combined with diet, exercise, and lifestyle changes.

What are the possible side effects or risks?

The most common side effects are gastrointestinal and include nausea, vomiting, diarrhea, constipation, bloating, or reduced appetite. Fatigue or dizziness may also occur, especially early in treatment. Rare but serious risks include pancreatitis, gallbladder disease, or thyroid tumors (seen in animal studies). Regular medical monitoring ensures safe and effective results.

Book an appointment

Leave us a message with your contact info and we will get back to you as soon as possible.

SCHEDULE APPOINTMENT